posaconazole

Known as: posaconazole [Chemical/Ingredient] 
A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome… (More)
National Institutes of Health

Related topics

Related topics

15 relations

Broader (4)

14-alpha Demethylase InhibitorsAntifungal AgentsTriazolesTrypanocidal Agents
16.7 ML posaconazole 18 MG/ML Injection [Noxafil]AzolesMycosesPosaconazole:MCnc:Pt:Ser/Plas:Qn
(More)

Narrower (2)

NoxafilSCH-56592

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
A four-part, randomized, crossover study with healthy subjects evaluated the effects of gastric pH, the dosing frequency and… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
 
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Posaconazole as salvage therapy for zygomycosis.
Zygomycosis, an infection that is associated with significant morbidity and mortality, is becoming common in immunocompromised… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we… (More)
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
The in vitro activity of the novel triazole antifungal agent posaconazole (Noxafil; SCH 56592) was assessed in 45 laboratories… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
BACKGROUND Conventional amphotericin B-based antifungal therapy for invasive fusariosis in patients with a hematologic malignancy… (More)
  • table 1
  • table 2
Is this relevant?
Review
2005
Review
2005
Posaconazole: a broad-spectrum triazole antifungal.
Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
AIMS This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B… (More)
  • table 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.
The pharmacokinetics, safety, and tolerability of posaconazole, an investigational triazole antifungal, were evaluated following… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?